All data are based on the daily closing price as of October 8, 2025
e

EuBiologics

206650.KQ
9.46 USD
0.05
+0.53%

Overview

Last close
9.46 usd
Market cap
344.71M usd
52 week high
12.48 usd
52 week low
6.82 usd
Target price
10.52 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
5.053
Price/Book Value
3.1106
Enterprise Value
305.30M usd
EV/Revenue
2.9266
EV/EBITDA
7.3349

Key financials

Revenue TTM
67.36M usd
Gross Profit TTM
67.36M usd
EBITDA TTM
11.83M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
137.10M usd
Net debt
N/A usd

About

EuBiologics Co., Ltd., a biopharmaceutical company, provides vaccines for pidemics in South Korea. It offers Euvichol, Euvichol Plus, and Euvichol-S, an oral cholera vaccine developed to prevent cholera; and EuCorVac-19, a subunit vaccine.The company also provides EcML, a vaccine for cell membrane, as well as offers COVID-19 diagnostic kits; and rCRM197, a diphtheria toxoid vaccine. In addition, it offers CMO services comprising of drug product production, cell bank production, drug product production, and drug substance production. Further, the company provides CRMO services, including production process development, formulation development, analyticals method development, and licensing and approval consulting service; and operates facilities that manufacture protein-based therapeutics and antibodies. Additionally, it offers contract testing services that include lot release, stability, raw material, and method validation testing services. EuBiologics Co., Ltd. was founded in 2010 and is headquartered in Seoul, South Korea.
  • Symbol
    206650.KQ
  • Exchange
    KQ
  • Isin
    N/A
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
  • Headquarter
    Seoul
  • Web site
    https://www.eubiologics.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top